Pharvaris (PHVS) Financials: Revenue & Earnings
PHVS$33.22+0.40 +1.22%
$2.32B
Market Cap
-10.38
P/E
19.57
Forward P/E
—
Score
Pharvaris (PHVS) Financials: Revenue & Earnings
PHVS price $33.22 +0.40 +1.22%
- Ticker
- PHVS
- Price
- $33.22
- Change
- +0.40 +1.22%
- Market cap ?
- $2.32B
- P/E ?
- -10.38
- Forward P/E ?
- 19.57
- Dividend yield ?
- 0.00%
- Beta ?
- -2.46
- Sector
- Healthcare
- Industry
- Biotechnology
Financials
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema…
Earnings and financials
Pharvaris N.V. (PHVS) trades at $33.22, with a market cap of $2.32B and a trailing P/E of -10.38. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Insights · Dividends · Forecast · Financials · Learn